Antiparkinsonian MAO Inhibitors (MAOIs)

Antiparkinsonian monoamine oxidase inhibitors (MAOIs) are a specialized subclass of neuroactive drugs—predominantly selective, irreversible or reversible inhibitors of monoamine oxidase type B (MAO-B)—designed to manage Parkinson’s disease

Antiparkinsonian monoamine oxidase inhibitors (MAOIs) are a specialized subclass of neuroactive drugs—predominantly selective, irreversible or reversible inhibitors of monoamine oxidase type B (MAO-B)—designed to manage Parkinson’s disease Clinically, these agents are indicated as monotherapy in the early stages of Parkinson’s disease to provide mild symptomatic motor control, or as adjunctive therapy to levodopa-carbidopa regimens in advanced stages to diminish motor fluctuations and "off" peri...

They function primarily by blocking the MAO-B isoenzyme responsible for central dopamine degradation, thereby enhancing striatal dopamine bioavailability and prolonging dopaminergic neurotransmission Clinically, these agents are indicated as monotherapy in the early stages of Parkinson’s disease to provide mild symptomatic motor control, or as adjunctive therapy to levodopa-carbidopa regimens in advanced stages to diminish motor fluctuations and "off" periods

They function primarily by blocking the MAO-B isoenzyme responsible for central dopamine degradation, thereby enhancing striatal dopamine bioavailability and prolonging dopaminergic neurotransmission

Representative medications in this class include selegiline, rasagiline, and safinamide